Galactosamine prevents ethinylestradiol-induced cholestasis

Area of Science:

• Hepatology
• Pharmacology
• Toxicology

Background:

• Ethinylestradiol (EE) is known to induce intrahepatic cholestasis in animal models.
• Ethinylestradiol 17beta-glucuronide, a derivative of EE, is a suspected mediator of this cholestatic effect.
• Understanding the role of glucuronidation in EE-induced cholestasis is crucial for elucidating its pathogenesis.

Purpose of the Study:

• To investigate the role of glucuronidation in the pathogenesis of ethinylestradiol (EE)-induced cholestasis.
• To determine if inhibiting glucuronidation can prevent EE-induced liver injury.
• To examine the effect of galactosamine on biliary secretory function in the presence of EE.

Main Methods:

• Administration of ethinylestradiol (EE) and galactosamine to experimental animals.
• Measurement of hepatic UDP-glucuronic acid (UDP-GA) levels.
• Assessment of biliary secretory function and serum liver injury markers.
• Use of [3H]EE to trace the excretion of EE glucuronide.

Main Results:

• Galactosamine significantly decreased hepatic UDP-GA levels and EE-17beta-glucuronide excretion.
• Galactosamine coadministration partially prevented EE-induced impairment of bile flow and bile salt secretion.
• Uridine coadministration partially reversed the anticholestatic effects of galactosamine.

Conclusions:

• The findings support the hypothesis that ethinylestradiol 17beta-glucuronide is involved in the pathogenesis of EE-induced cholestasis.
• Inhibition of glucuronidation via galactosamine partially prevents EE-induced cholestasis by reducing UDP-GA availability.
• This study highlights the importance of glucuronidation in estrogen-induced liver injury.